A Phase I/II Trial of Dasatinib in Combination With Trastuzumab and Paclitaxel in the First Line Treatment of Her2-Positive Metastatic Breast Cancer (Mbc) Patients.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Mar 2017
At a glance
- Drugs Dasatinib (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 22 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 12 Dec 2015 Trial design of phase II part of this study presented at the 38th Annual San Antonio Breast Cancer Symposium.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History